MET and renal cell carcinoma: In addition, Mori et al. [43] found that cellular-mesenchymal epithelial transition factor (c-Met) could be used as a therapeutic target for RCC, creating anti-human c-Met targeted CAR T cells (Fig. 2C) and studying their anti-tumor effects in an orthotopic mouse model.